Innospace, SpaceLynkTech, and InterGravity Enter Business Agreement
On January 8, representatives Kim Su-jong of Innospace, Yoon Hak-soon of SpaceLynkTech, and Lee Ki-joo of InterGravity Technologies gathered for a memorandum of understanding (MOU) signing ceremony at the SpaceLynkTech Business Center, as captured in a commemorative photo provided by Innospace.
According to Kim Seung-jun of News1, Innospace announced on the 9th that it signed an agreement with SpaceLynkTech and InterGravity Technologies for mutual cooperation in the R&D and commercialization of transportation and recovery platforms and devices for space medicine research and new drug development projects.
Innospace is a private space launch company, SpaceLynkTech is involved in space medicine, and InterGravity Technologies focuses on space exploration.
Through this agreement, the companies will integrate SpaceLynkTech’s technology for space medicine research and pharmaceutical platforms, Innospace’s custom space launch technology for space medicine, and InterGravity’s technology related to orbital transport and surface recovery. The goal is to complete the full cycle of element technologies needed for space manufacturing and recovery and to advance commercialization cooperation.
SpaceLynkTech was recently selected as the leading company for the ‘Overcoming Medical Challenges with Innovative Space Medicine Technology Development’ project under the second Korean ARPA-H initiative.
Innospace is preparing for the launch of its self-developed HANBIT-Nano rocket for South Korea’s first private commercial satellite launch in July. InterGravity is developing orbital transport and recovery ships, leveraging a non-toxic high-efficiency propulsion system.
Kim Su-jong, CEO of Innospace, remarked, “It is very meaningful to gain the opportunity to develop space launch vehicles and systems for transporting space medicine modules and to pioneer a new market in the field of space medicine.”
Yoon Hak-soon, CEO of SpaceLynkTech, stated, “It’s significant to establish a foothold for South Korea to be recognized as a major player in the fierce global competition for new drug development utilizing space.”
Lee Ki-joo, CEO of InterGravity, emphasized, “With leading companies like Barada entering the production of high-value pharmaceuticals in space, we hope that the joint creation and rapid demonstration of space bio-logistics solutions by the three companies will yield future food resources from space.”